Sugar Coatings on Receptors Affect How Well Peptide Hormones Like GLP-1 and Amylin Work
N-glycosylation (sugar modification) of peptide hormone receptors is critical for proper ligand binding and activation, with implications for drug development targeting GLP-1, amylin, and related receptors.
Quick Facts
What This Study Found
The review reveals that N-glycosylation enhances pharmacodynamic properties of class B1 GPCRs including receptor-ligand binding and activation potency. Key findings by receptor type:
- Calcitonin and amylin receptors: N-glycosylation apparently enhanced binding affinity of peptide ligands, with specific critical N-glycosylation sites identified
- GIP and secretin receptors: Also have critical individual N-glycosylation sites that drive the whole glycosylation effect
- GLP-1 and CRF1 receptors: Each glycosylation site collectively contributes to the overall effect, rather than one site being dominant
- Calcitonin gene-related peptide receptor: Has identified critical N-glycosylation sites
The review also addresses potential mechanisms by which sugar modifications enhance peptide ligand binding affinity at the molecular level.
Key Numbers
How They Did This
This is a narrative review summarizing published research on N-glycosylation effects across class B1 GPCR family members. The authors focused on three functional parameters: cell-surface receptor expression, ligand binding affinity, and receptor activation potency. They compared glycosylation patterns and functional dependencies across multiple receptor systems.
Why This Research Matters
Many of today's blockbuster peptide drugs — including semaglutide (GLP-1), tirzepatide (GIP/GLP-1), and calcitonin — work by binding to class B1 GPCRs. Understanding that sugar modifications on these receptors significantly affect how peptide drugs bind and activate them is essential for accurately evaluating drug potency and designing better therapeutics.
The Bigger Picture
As the peptide drug market expands rapidly — with GLP-1 agonists alone generating tens of billions in annual revenue — understanding the molecular details of receptor interaction becomes increasingly important. This review highlights a often-overlooked factor (glycosylation) that could affect drug development screening and lead optimization for the next generation of peptide therapeutics.
What This Study Doesn't Tell Us
The review notes that several class B1 GPCR family members remain unexplored regarding their N-glycosylation effects. Most studies reviewed used cell-based systems that may not perfectly replicate in vivo glycosylation patterns. The mechanisms by which glycosylation enhances binding remain incompletely understood.
Questions This Raises
- ?How does individual patient variation in receptor glycosylation affect their response to peptide drugs like semaglutide?
- ?Could glycosylation differences explain some of the variability in GLP-1 agonist effectiveness across patients?
- ?Should drug screening assays be redesigned to better account for receptor glycosylation states?
Trust & Context
- Key Stat:
- Critical for most class B1 GPCRs N-glycosylation is essential for normal receptor function across the family that includes GLP-1, GIP, amylin, calcitonin, and secretin receptors
- Evidence Grade:
- This is a narrative review synthesizing published biochemical and pharmacological studies. It provides a useful overview of the field but does not generate new experimental evidence.
- Study Age:
- Published in 2025, this review captures the current understanding of glycosylation effects on peptide hormone receptors, relevant to the rapidly expanding field of peptide therapeutics.
- Original Title:
- N-glycosylation effects on the function of class B1 G protein-coupled receptors.
- Published In:
- Carbohydrate research, 557, 109641 (2025)
- Authors:
- Lee, Sangmin(4), Jin, Jeongwoo, Song, Hyeseon, Jang, Jaehyeok
- Database ID:
- RPEP-12025
Evidence Hierarchy
Frequently Asked Questions
What is N-glycosylation and why does it matter for peptide drugs?
N-glycosylation is the process of attaching sugar chains to proteins. When these sugars are attached to hormone receptors, they can significantly change how well peptide drugs bind to and activate those receptors. Ignoring this factor during drug development could lead to inaccurate predictions of how drugs will work in the body.
Which popular peptide drugs are affected by receptor glycosylation?
Drugs targeting class B1 GPCRs, including GLP-1 agonists (semaglutide/Ozempic, liraglutide), GIP/GLP-1 dual agonists (tirzepatide/Mounjaro), calcitonin (used for osteoporosis), and amylin analogues (pramlintide) all work through receptors where glycosylation affects binding and activation.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-12025APA
Lee, Sangmin; Jin, Jeongwoo; Song, Hyeseon; Jang, Jaehyeok. (2025). N-glycosylation effects on the function of class B1 G protein-coupled receptors.. Carbohydrate research, 557, 109641. https://doi.org/10.1016/j.carres.2025.109641
MLA
Lee, Sangmin, et al. "N-glycosylation effects on the function of class B1 G protein-coupled receptors.." Carbohydrate research, 2025. https://doi.org/10.1016/j.carres.2025.109641
RethinkPeptides
RethinkPeptides Research Database. "N-glycosylation effects on the function of class B1 G protei..." RPEP-12025. Retrieved from https://rethinkpeptides.com/research/lee-2025-nglycosylation-effects-on-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.